Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04248452 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body

StatusActive, Not Recruiting
PhasePhase 3
Started
View on ClinicalTrials.gov ↗

Record History

  1. 6 versions Re-verified since Feb 27, 2026, no change to tracked fieldsv19-v24
  2. Trial status: Recruiting to Active, Not Recruiting
    • Site details revised at 453 of 453 sites
    v18
  3. 4 versions Re-verified since Sep 15, 2025, no change to tracked fieldsv14-v17
  4. Site details revised at 1 of 453 sitesv13
  5. Study sites: 446 to 453v12
Show 10 earlier versionsHide 10 earlier versions
  1. Study sites: 388 to 446v11
  2. Primary and study completion dates: Dec 31, 2023 to Mar 31, 2028v10
  3. Start date: Feb 6, 2020 to May 26, 2020v9
  4. Study sites: 381 to 388v8
  5. Study sites: 367 to 381v7
  6. Re-verified, no change to tracked fieldsv6
  7. Study sites: 255 to 367v5
  8. Study sites: 177 to 255v4
  9. Trial status: Not Yet Recruiting to Recruiting
    • Study sites: 0 to 177
    v3
  10. Start date: Apr 21, 2020 to Feb 6, 2020v2
  1. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This phase III trial studies how well the addition of radiotherapy to the usual treatment (chemotherapy) works compared to the usual treatment alone in treating patients with esophageal and gastric cancer that has spread to a limited number of other places in the body (oligometastatic disease). Radiotherapy uses high energy x-rays, gamma rays, or protons to kill tumor cells and shrink tumors. Drugs used in usual chemotherapy, such as leucovorin, 5-fluorouracil, oxaliplatin, and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Adding radiotherapy to the usual chemotherapy may work better compared to the usual chemotherapy alone in treating patients with esophageal and gastric cancer.
Trial Details
NCT Number NCT04248452
Lead Sponsor ECOG-ACRIN Cancer Research Group
Collaborators: National Cancer Institute (NCI)
Conditions
(from sponsor)		 Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IVA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVA Gastric Cancer AJCC v8, Clinical Stage IVB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IVB Gastric Cancer AJCC v8, Metastatic Esophageal Adenocarcinoma, Metastatic Gastric Adenocarcinoma +6 more
Related terms Adenocarcinoma Of Esophagus
Enrollment 314 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov